Bristol-Myers Squibb Co
BMY
ISIN null / Valor 914188
Bristol-Myers Squibb Co
UMushroom community rating:
About company
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines, with a commercial focus on oncology, hematology, immunology and cardiovascular disease. Its marketed portfolio includes immuno‑oncology therapies such as nivolumab (Opdivo), the widely used anticoagulant apixaban (Eliquis, co‑developed with Pfizer) and a range of treatments for blood cancers and autoimmune conditions, while its pipeline covers targeted small molecules, biologics and emerging modalities including cell therapies. The company generates revenue from global product sales, licensing and collaboration agreements and supports those commercial activities with substantial R&D and clinical development operations; its 2019 acquisition of Celgene significantly expanded its hematology and oncology franchises. Headquartered in New York, Bristol‑Myers Squibb operates worldwide as a publicly traded pharmaceutical firm.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
136760 M
Market cap (USD)
4,670,519
Daily traded volume (Shares)
57.55 / 56.05
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Nojus Okleiteris
Markus Dathe
EQUITIES OF THE SAME SECTOR
